Antitumor activity of the novel vascular targeting agent zd6126 in a panel of tumor models

Clinical Cancer Research

Volumn 8, Issue 6, 2002, Pages 1974-1983

  Blakey, David C ^a   Westwood, F Russell ^a   Walker, Mike ^a   Hughes, Gareth D ^a   Davis, Peter D ^b   Ashton, Sue E ^a   Ryan, Anderson J ^a  

^a ASTRAZENECA   (United Kingdom)

^b Angiogene Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; N ACETYLCOLCHINOL PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTRON MICROSCOPY; ENDOTHELIUM; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RETINA BLOOD VESSEL OCCLUSION; SOLID TUMOR; THROMBOSIS; TUMOR NECROSIS; TUMOR VASCULARIZATION; XENOGRAFT;

3T3 CELLS; ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0036278972     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Vascular attack as a therapeutic strategy for cancer
2. Tumor vasculature as a target for cancer therapy
3. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
4. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
5. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death
6. Antiangiogenesis drugs target specific cancers, mechanisms
7. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice
8. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine. Evidence for a vascular mechanism
9. Vinca alkaloids: Antivascular effects in a murine tumor
10. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy
11. The interaction with tubulin of a series of stilbenes based on combretastatin A-4
12. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
13. Taxol: A novel investigational antimicrotubule agent
14. Antivascular approaches to solid tumor therapy: Evaluation of vinblastine and flavone acetic acid
15. Effects of novel and conventional anticancer agents on human endothelial permeability: Influence of tumor-secreted factors
16. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
17. Effects of combretastatin A-4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo
18. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumor perfusion and energetic status
19. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700
20. ZD6126: A new agent causing selective damage of tumor vasculature
21. The novel vascular targeting agent ZD6126 causes rapid morphology changes leading to endothelial cell detachment at noncytotoxic concentrations
22. Targeting the vasculature of solid tumors
23. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
24. Mechanisms of enhancement of the antitumor activity of melphalan by the tumor-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid
25. Antivascular approaches to solid tumor therapy: Evaluation of combretastatin A4 phosphate
26. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma
27. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma
28. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy
29. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors
30. Angiogenesis, neovascular proliferation, and vascular pathophysiology as targets for cancer therapy